ivWatch, LLC

ivWatch, LLC Our mission is bold and clear: STOP IV HARM. Continuous monitors exist to keep track of patients’ heart, blood oxygen levels and pulse rates.

ivWatch is redefining IV therapy safety with the only FDA-cleared and CE-marked medical device in the world designed to detect IV infiltrations and extravasations early, before they cause patient harm. ivWatch, LLC is a medical device company focused on improving the safety and effectiveness of intravenous (IV) therapy. IV therapy is a basic yet critical component of care in hospital and outpatien

t settings, but it has a high failure rate. Until now, no technology has been available to continuously monitor the health of a patient’s IV site, and whether drugs or fluids are being delivered through the vein or leaking into the tissue. The ivWatch Model 400 is a FDA-cleared device to help clinicians monitor the status of a patient’s IV to aid in the early detection of peripheral IV infiltrations and extravasations. Through the use of non-invasive sensor technology, the ivWatch Model 400 can help reduce potentially serious medication dosing errors and associated patient harm from infiltration events. A continuously monitored peripheral IV also offers an alternative to more intrusive vascular access devices when medically indicated. Use of these devices has increased, but can also pose significant risk of harm to patients and greater cost and liability for hospitals. ivWatch has the potential to transform IV therapy by improving patient care and safety, and offering health care providers a much-needed, reliable and cost-effective solution for continuously monitoring peripheral IVs.

We hear all the time “It’s just saline” or “I’m not infusing a vesicant drug.” These are not reasons to turn a blind eye...
06/17/2026

We hear all the time “It’s just saline” or “I’m not infusing a vesicant drug.”

These are not reasons to turn a blind eye. IVs are frequently draped in the ORs, or overlooked during shift change, and periodic checks are often missed. When not checked for hours, even “just saline” can easily turn into a huge problem like compartment syndrome and a treatment plan of a fasciotomy.

Every drug, every infusion, is critical and needs continuous site checks.

More about saline infiltrations: https://www.ivwatch.com/2026/05/26/saline-infiltration-the-overlooked-risk-in-routine-intravenous-therapy/

Clinicians spot problems early. You see workflow gaps, patient safety risks, delays, burnout triggers, and inefficiencie...
06/11/2026

Clinicians spot problems early. You see workflow gaps, patient safety risks, delays, burnout triggers, and inefficiencies long before they show up in a dashboard.

But many strong ideas never move forward because they’re presented as:
· “This is frustrating”
· “We should fix this”
· “Patients don’t like it”

Executives usually need something different:
· Measurable impact
· Operational alignment
· Financial relevance
· Strategic fit
· A clear implementation path

Here’s a framework clinicians can use to turn frontline observations into executive-ready pitches. https://www.ivwatch.com/2026/06/02/from-idea-to-impact-how-clinicians-can-successfully-pitch-new-technology-in-their-hospital/

06/11/2026

Iron deficiency anemia affects up to 1 in 3 pregnant women globally—yet one of its most preventable complications is often overlooked.¹

While IV iron therapy is helping clinicians act faster, it also introduces a serious risk: extravasation injuries that can cause permanent skin damage and lasting psychological impact.

At Frimley Health NHS Foundation Trust, Andrew Barton and team took a different approach—combining awareness, protocol, and continuous monitoring technology.

The result?
- Zero iron extravasation injuries after implementation
- Earlier detection and improved patient safety

Andrew Barton is helping pave the way forward with the NIVAS IV safety toolkit—where ivWatch is part of the solution.

Read more about Iron extravasations here: https://lnkd.in/e2iA6Y3u

1. https://lnkd.in/e4Ziknvz

Peripheral IV infiltration and extravasation injuries remains a significant patient safety challenge across the U.S. hea...
06/09/2026

Peripheral IV infiltration and extravasation injuries remains a significant patient safety challenge across the U.S. healthcare system—particularly in pediatric settings, where patients are most vulnerable and early signs are often harder to detect.

Addressing this risk requires more than awareness. It requires proactive, system‑level approaches that strengthen IV therapy practices and reduce preventable harm.

ivWatch is proud to partner with leading pediatric hospitals that recognize the urgency of this issue and are taking meaningful steps to improve safety for their youngest patients.

Improving IV safety takes more than new technology—it requires a shift in how teams approach infusion care. Real progres...
06/04/2026

Improving IV safety takes more than new technology—it requires a shift in how teams approach infusion care. Real progress happens when innovation is paired with clinician education, collaboration, and a shared commitment to patient safety.

By working alongside clinical teams, we’re helping address preventable IV infiltration and extravasation events through a proven, proactive approach that supports earlier intervention, greater clinician confidence, and better outcomes.

This is about building safer systems, empowering nurses, and raising the standard of IV therapy—together.

Fresh energy out of the Emirates Critical Care Conference in Dubai, where IV safety and innovation took center stage.  I...
06/03/2026

Fresh energy out of the Emirates Critical Care Conference in Dubai, where IV safety and innovation took center stage.

It's energizing to see critical care teams leaning into proactive strategies to reduce extravasation risk and advance safer peripheral vasopressor practices.

The focus on earlier detection and continuous monitoring is gaining real traction—and driving meaningful progress in patient safety.

More to come as this momentum builds.

Join our movement to end avoidable IV harm. ivWatch is advancing IV therapy safety worldwide by partnering with hospital...
06/02/2026

Join our movement to end avoidable IV harm.

ivWatch is advancing IV therapy safety worldwide by partnering with hospitals and healthcare leaders that are evangelists for change. We’re bridging clinical practice with smarter technology to advance patient safety priorities.

Each interaction, each visit, and each implementation of our product moves us closer to a shared goal: empowering clinicians, improving outcomes, and raising the bar for infusion care no matter where in the world IV therapy is needed.

We’re proud to work alongside healthcare teams who are redefining what’s possible in IV therapy. Through early detection...
05/28/2026

We’re proud to work alongside healthcare teams who are redefining what’s possible in IV therapy. Through early detection technology and real-time data, clinicians are empowered to identify risks sooner, take action and deliver safer care.

Normal saline may be classified as low risk — but a missed infiltration can still lead to devastating patient harm.Compl...
05/27/2026

Normal saline may be classified as low risk — but a missed infiltration can still lead to devastating patient harm.

Complications can escalate quickly—compartment syndrome requiring an emergency fasciotomy, nerve ischemia and compression leading to sensory or motor deficits, and even skin necrosis requiring surgical debridement.

Our latest article explores:
• Why saline infiltration remains underrecognized
• The mechanism behind serious tissue injury
• Which patient populations are most vulnerable
• Why delayed detection is the real systems problem
• Evidence-based prevention and monitoring strategies

Early detection matters — even for “low-risk” fluids.

Read more: https://www.ivwatch.com/2026/05/26/saline-infiltration-the-overlooked-risk-in-routine-intravenous-therapy/


It has never been more evident that the current standard of care in IV therapy is falling short. As IV infiltration rate...
05/26/2026

It has never been more evident that the current standard of care in IV therapy is falling short. As IV infiltration rates continue to rise, relying on visible injury before taking action remains an outdated practice.

In today’s clinical environment, technology must evolve to meet the urgency of patient safety. That’s why we developed ivWatch—a clinically validated, continuous monitoring solution that evaluates IV sites five times per second, identifying risk at the earliest onset of an IV injury, before visible signs appear.

Learn how ivWatch technology is transforming IV care and helping clinicians detect infiltration sooner: https://www.ivwatch.com/

Address

700 Tech Center Parkway, Suite 300
Newport News, VA
23606

Opening Hours

Monday 8:30am - 6pm
Tuesday 8:30am - 6pm
Wednesday 8:30am - 6pm
Thursday 8:30am - 6pm
Friday 8:30am - 6pm

Alerts

Be the first to know and let us send you an email when ivWatch, LLC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to ivWatch, LLC:

Share